Experimental models to study the effect of agents on penile erection usually include electrical stimulation of peripheral nerves in anesthetized animals combined with systemic or intracavernous injection of drugs. The objective of this study was to demonstrate that conscious rabbits can be used as a simple and quantitative model for the assessment of compounds that show potential for the treatment of erectile dysfunction. Erection was assessed by measuring the length of uncovered penile mucosa before and after the intravenous (i.v.) administration of agents. Animals did not require anesthesia during the course of the study. The phosphodiesterase 5 (PDE5) inhibitors vardena®l 6 HCl (hereafter called vardena®l) and sildena®l were given intravenously, and measurements were taken for 0 ± 5 h. The effects of phentolamine and milrinone were also evaluated. Vardena®l (0.1 ± 3 mgakg) induced dose-dependent penile erections in conscious rabbits following i.v. administration. The ef®cacy of vardena®l was potentiated, and the minimal effective dose was reduced signi®cantly to 0.01 mgakg by simultaneous administration of the nitric oxide (NO) donor sodium nitroprusside (SNP). Administration of the NO-synthase inhibitor L-NAME abolished the effect. Sildena®l was effective in this model after i.v. administration. The a-adrenergic receptor antagonist phentolamine (0.1, 0.3 and 1 mgakg i.v.) induced erections with a slower t max compared with vardena®l and sildena®l. Intravenous administration of the PDE3 inhibitor milrinone (1 mgakg i.v.) was less effective than the PDE5 inhibitor vardena®l. The conscious rabbit is a suitable and reliable model for the evaluation of compounds with potential for the treatment of erectile dysfunction. This was demonstrated using compounds that target different signaling pathways that induce smooth muscle relaxation in the penis.
Introduction
The development of pharmacological agents that may have utility in the treatment of erectile dysfunction is currently of intense interest to companies and academic centers. While in vitro techniques using corpus cavernosal tissues permit an initial screening of appropriate pharmacological activity, it is always important to verify that the required activities can be documented in vivo. Previous models have typically used an anesthetized model, whereby the nerves to the penis are stimulated and then the ability of the pharmacological agents are evaluated by their modulatory effect on the subsequent erection. 1,2 While these models have been an important tool in the veri®cation of pharmacological activity, they have limitations.
They require complicated surgery with anesthesia, and recovery time after surgery and between stimulation episodes limits the number of times that drugs can be evaluated in an animal. In addition, anesthesia may in¯uence the activity of agents. An ideal experimental model would utilize a conscious animal without requiring surgical intervention. The animal could be used repeatedly, improving on the statistical strength, since individual responsiveness would be minimized.
An earlier report has shown preliminary data in such a model. In 1993, Naganuma et al, were able to show that intramuscular injections of neuroleptics were able to induce an erection of the penis of the rabbit. 3 By measuring the length of the exposed mucosa in millimeters, a quantitative measure of the pharmacological effect was found. The difference between this and other models is that it was not just modulating the induced response, but that it was an inherent property of the agents. While this model did not require sexual or direct stimulation, these agents nevertheless were seen to produce erections by themselves. One premise of this method is that the agents should be able to produce erections by themselves at higher doses than are normally effective. Only agents that produce an effect without severely affecting other physiological systems at these high concentrations can be evaluated. Thus, if a compound can produce an erection in the absence of sexual stimulation without adverse effects on the animal, then this would provide support for it being a good candidate for further development. In addition, if the effect is potentiated by substances which are known to be released during sexual stimulation, then this would provide further support for its candidacy.
Penile erection is a hemodynamic process involving relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. 4, 5 The local control of smooth muscle relaxation is regulated by contraction and relaxation forces exerted via speci®c neurotransmitter and vasoactive mechanisms. Nitric oxide is the principal non-cholinergic non-adrenergic neurotransmitter mediating smooth muscle relaxation through its activation of guanylate cyclase. 6 ± 9 This results in an increased intracellular cyclic nucleotide monophosphate (cGMP) level. In penile tissue, cGMP is predominantly metabolized by cGMP-phosphodiesterase 5 (PDE5). 10, 11 Inhibition of PDE5 increases cGMP, enhances relaxation of smooth muscle in the corpus cavernosum, and induces penile erection, and this is the basis of the mechanism of action of sildena®l currently used in the treatment of erectile dysfunction.
Other contributors to smooth muscle relaxation in the penis are through the VIP, NPY-and CGRPmediated pathways. The transduction of the signal from these pathways is through cyclic adenosine monophosphate (cAMP)-dependent pathways. 6 Phosphodiesterase 3 (PDE3) degrades cAMP and is localized to some extent in the corpus cavernosum. 12, 13 Agents which inhibit PDE3 and increase cAMP could also have the potential to induce erections. One such agent is milrinone, which is currently being evaluated for erectile dysfunction. 13 Phentolamine, by blockinga-adrenergic receptors, can indirectly modulate the Ca 2 release from sarcoplasmatic reticulum through an IP3-dependent mechanism. 14, 15 If a conscious animal model could show that these compounds were effective in inducing erections, then it would become a useful tool in screening these types of compounds before they are taken further into clinical development. Rabbits are used widely as models for investigation of erectile dysfunction because of a good correlation between contraction and relaxation in the human and rabbit corpus cavernosum. 16 ± 18 The objective of this study was to demonstrate that conscious rabbits can be used as a simple and quantitative model for the assessment of intravenously injected compounds which have potential for the treatment of erectile dysfunction through their activity on the various mechanisms described above.
Methods

Animals
Six adult male chinchilla rabbits (Charles River, Kiûlegg, Germany) with an average weight of 3.5 ± 4.5 kg were used in each dosing group. The rabbits were housed individually in cages (EBECO GmbH), food and drink were available ad libitum for 2 h a day, and the animals were kept in the animal facility for at least 1 week after arrival before being tested. Room lights were on from 8 am to 6 pm, and room temperature was 22 ± 24 C. For this study, an indwelling catheter ®lled with saline was inserted into a marginal ear vein and taped in position. The animals became accustomed to handling and were not disturbed by repeated handling. Typically, the drugs were given into the ear vein, followed by a small volume of saline. The time was noted and, at the appropriate time, the animals were gently removed from the cage and held by one individual, and the length of any uncovered penile mucosa was measured using a caliper ( Figure  1a and 1b). The penis was not handled at all to avoid direct stimulation. The animals tolerated this well. 
Rabbit model to study vardena®l hydrochloride E Bischoff and K Schneider
In this series of experiments, those measuring the penis were not blinded to the administered drug. Between measurements, the animals were returned to their cage and were given access to water and food. Each animal was used multiple times for different doses and for different agents with adequate washout periods between. The minimal time between each experiment for each animal was 10 days. Each dose was repeated multiple times in six different animals.
Drugs used
Vardena®l (Bayer, Pharma Chemical Research, Wuppertal, Germany), a PDE5 inhibitor with purinone type structure, and sodium nitroprusside (SNP) was dissolved in 0.9% NaCl, sildena®l. (Bayer, Pharma Chemical Research, Wuppertal, Germany), phen-tolamine and milrinone (SigmaAldrich Chemie GmbH, Steinheim, Germany), were dissolved in Transcutol (Gattefosse GmbH, Weil-amRhein, Germany) and diluted with 20% Cremophor-EL (BASF AG, Ludwigshafen, Germany) in distilled water at a ratio of 3:7. The compounds were administered into the ear vein in a volume of 0.5 mlakg.
Time course of measurements
Penile erection was evaluated by measuring the length to the nearest millimeter of the uncovered penile mucosa with a sliding caliper at 5, 10, 15, 30, 50, 60, 90, and 120 min after administration of the test compounds and continued hourly for up to 5 h (Figure 1a and 1b) . Mean values were calculated and results expressed as means AE s.e.m. The area under the curve (AUC) was calculated by an integration program (Graph Pad Software, San Diego). Controls were performed with the corresponding solvents. It should be noted that physiological parameters such as heart rate and blood pressure were not measured in this conscious-rabbit model.
Results
PDE5 inhibition
Vardena®l. Intravenous administration of saline vehicle and the subsequent handling of the animals did not cause any erections over the 5-h observation period. However, i.v. vardena®l did show a dosedependent increase in the length of penile mucosa exposed (Figure 2 ). The minimal effective dose was 0.1 mgakg, which produced a mean maximum exposed mucosa of 3 mm at about 20 min. Progressively higher doses caused a more rapid response with onset of action within 5 min and a maximal response occurring within 10 ± 15 min of administration. Doses of 1 mgakg and 3 mgakg produced a maximal response in this model of 15 AE 3 mm and 17 AE 2 mm respectively of exposed penile mucosa. There was no difference between the response to the 1 mgakg and the 3 mgakg dose. The response gradually waned, but there was still a substantial, measurable erection after 2 h at the highest doses. Table 1) . Doses of 0.01 and 0.03 mgakg i.v. induced no erection by themselves, but with coadministration of SNP, erections clearly greater than induced by SNP alone were found. The higher doses of 0.1 and 0.3 mgakg i.v. induced weak erections which were potentiated by SNP. The data Figure 2 The length of uncovered penile mucosa was measured after vardena®l was administered intravenously in the indicated doses into the ear veins of conscious rabbits.
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L-NAME abolishes the effects of vardena®l. Intravenous administration of the NO-synthesis inhibitor L-NAME (10 mgakg) 10 min before injection of vardena®l (1 mgakg) nearly completely suppressed the erection induced by vardena®l (Figure 4 ). Although not shown in the ®gure, the highest dose of vardena®l (3 mgakg i.v.) was found to be markedly less effective when given in the presence of L-NAME. This demonstrates that synthesis of NO is a prerequisite for the ef®cacy vardena®l in this animal model.
Sildena®l. Sildena®l, another well-studied PDE5 inhibitor, also induced dose-dependent erections in conscious rabbits after i.v. administration of 1, 3 and 5 mgakg. The onset of action and time course of erection were similar to those of vardena®l in this model ( Figure 5 ). The minimum effective dose was approximately 1 mgakg, and the 3-mgakg dose was approximately equivalent to 0.3 mgakg of vardena®l.
The maximum dose of sildena®l was not determined for technical solubility reasons, since the citrate formulation was not available at the time of this experiment.
PDE3 inhibition
Milrinone, a selective PDE3 inhibitor (IC50 200 nM), was effective after i.v. administration of Figure 4 The length of uncovered penile mucosa was measured after the i.v. administration of L-NAME (10 mgakg) in rabbits, followed 10 min later by an i.v. injection of vardena®l (1 mgakg). For comparison, vardena®l (1 mgakg) without L-NAME was given. Figure 5 The length of uncovered penile mucosa was measured after sildena®l was administered intravenously in the indicated doses into the ear veins of conscious rabbits.
Rabbit model to study vardena®l hydrochloride E Bischoff and K Schneider 1 mgakg. The onset of action was about 10 min, and the time course was similar to that seen with vardena®l and sildena®l ( Figure 6 ). Only one dose was studied, the purpose being to demonstrate that the model was also effective for these PDE3-speci®c inhibitors.
a-Adrenergic receptor blockade. Intravenous administration of phentolamine (0.1, 0.3, and 1 mgakg) induced strong and long-lasting erections, with a duration of 2 ± 5 h (Figure 7 ). In this case, the onset of action was relatively rapid, but the maximal effect was not reached until up to 2 h later at the highest doses.
Discussion
This study was able to demonstrate that the agents that cause relaxation of smooth muscle and increased blood¯ow of the penis were all able to induce erections in the conscious rabbit's penis without the need of concurrent sexual stimulation. The effects of the tested compounds on the erection were dose dependent. This implies that the model is very suitable for studying and screening compounds for this activity. In other commonly used models, anesthetized rabbits or other animals have been used for the study of penile erection. The intracavernosal pressure is recorded during electrical stimulation of peripheral nerves and the systemic or intracavernous injection of drugs. 17 ± 18 These models require complicated surgery, are invasive and, in addition, anesthesia may in¯uence the activity of the drugs. In this model, the measurements are simple to perform and can be made to the nearest millimeter leading to reproducible results. With training and practice, the results are consistent. Several individuals have performed these measurements with similar results. For improved strictness of protocol, those carrying out the measurements can be blinded to the drug to avoid potential operator bias.
PDE5 inhibitors induced erections in these animals. In this series, sildena®l was used primarily as a reference model, since it is currently approved for the treatment of erectile dysfunction. 19 This study evaluated vardena®l in more detail, since it has been shown to be more potent on a weight basis than sildena®l (in vitro studies, publication in preparation). 20 The ef®cacy of vardena®l in this model was shown to be heightened by the presence of NO donors, and this would correlate with the bene®ts of PDE5 inhibitors seen at the time of sexual arousal. During sexual stimulation, smooth muscle relaxation in the corpus cavernosum and its associated arterioles is mediated by NO, which is released from nerve terminals of NANC neurons in the penis. NO stimulates guanylate cyclase and increases the synthesis of cGMP. Under the experimental conditions of this animal model, the rabbits are not sexually stimulated. This may explain the high doses which are necessary for induction of an erection compared with the oral doses of sildena®l which are used in oral treatment in man. 19 Similarly, the doses of vardena®l currently being evaluated clinically produce effects with oral doses much lower than the active doses in this study. An NO donor such as SNP could stimulate the release of NO from sexual stimulation and enhance the ef®cacy of the PDE5 inhibitor. The effective doses of vardena®l in the presence of NO were reduced to a normally subthreshold dose of 0.03 mgakg i.v. This dependence of the compound's ef®cacy on the presence of NO, which is also supported by the Figure 7 The length of uncovered penile mucosa was measured after phentolamine was administered intravenously in the indicated doses into the ear veins of conscious rabbits. Figure 6 The length of uncovered penile mucosa was measured after milrinone (1 mgakg) was administered intravenously into the ear veins of conscious rabbits.
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The model was also effective in demonstrating the erection-generating properties through two other mechanisms. PDE3 metabolizes cAMP and is localized to a certain extent in the corpus cavernosum and it was found that the PDE3 inhibitor milrinone was effective in inducing erection in this model. Similarly, phentolamine has been used for the treatment of erectile dysfunction, and this modulates indirectly the intracellular calcium by an IP3-mediated process by a-receptor blockade. This was also shown to be clearly effective in this consciousrabbit model. The ef®cacy of the tested compounds in modulating different signaling pathways which induce smooth muscle relaxation suggest that the conscious-rabbit is a simple and valid model for the assessment of compounds with potential for the treatment erectile dysfunction.
This model also has great potential for use as a screening tool. The dosing strategy, time course of activity, and interactions with other compounds or endogenous synthesized transmitters like NO could be evaluated in these animals. Since no surgery is involved, the recovery time between doses is potentially limited to the washout time of the drug. However, in this series of experiments, 10 days were allowed between experiments on each animal. There are severe ethical limitations on subjecting animals to repeated, invasive surgery. This technique would avoid this problem, with no surgery and no anesthesia to affect the health and well-being of the animal. Cross-over studies can be employed, potentially improving the statistical accuracy and further limiting the number of animals required to complete a study.
This technique thus offers several methodological advantages as a screening model for compounds with erection-stimulating properties. It was found to be clearly successful in demonstrating the erectionstimulating properties of vardena®l, a new PDE5 inhibitor.
